Big Phar­ma's in­creas­ing M&A en­thu­si­asm; Manchin, Schumer reach deal on drug pric­ing; Earn­ings re­caps; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With Am­ber out on a well-de­served va­ca­tion this week, we’ve put this week’s re­port to­geth­er. It’s been a fast-paced week, abuzz with a litany of Q2 earn­ings calls that pro­vide an in­side look in­to the work­ings of Big Phar­ma. Thanks for read­ing, have a great week­end, and see you next week. — Kyle LaHu­cik and Paul Schloess­er

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.